|Articles|February 1, 2012
- Pharmaceutical Executive-02-01-2012
- Volume 0
- Issue 0
Pharmaceutical Executive Digital Edition - February 2012
Brand of the Year : Abbott's Humira
Advertisement
Articles in this issue
about 14 years ago
How to Choose a Medical Animatorabout 14 years ago
Money for Nothing, Patents for Free?about 14 years ago
Trying Trials at GC-2about 14 years ago
Prizing the Eye : Brent Saunders, CEO Bausch + Lombabout 14 years ago
Brand Success: It's Not Serendipityabout 14 years ago
Brazil Report: A Bold Player Bloomsabout 14 years ago
Of Farms, Beaches … and Genericsabout 14 years ago
FDA Social Media Guidelines: Irresponsible?about 14 years ago
Time to Appoint a 'Chief Patient Officer'?about 14 years ago
Japanese Knowledge Brought to BrazilNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Bayer Shares Briefly Dip After Activist Investor Offloads Millions of Dollars in Company Stock
2
Pharmaceutical Executive Daily: FDA Issues Warning Letter to ImmunityBio
3
Pharma M&A Roundup: Merck to Acquire Terns Pharmaceuticals, Shionogi to Acquire 50% of Apnimed’s Ownership of Shionogi-Apnimed Sleep Science
4
FDA Sends Warning Letter to ImmunityBio for Misleading Claims in Advertisement
5